Visalytics
Visalytics
approved EB-2 (NIW)

Research Analyst

Neuromuscular Diseases · China · 2025-01-28

Processing Time
122 days
Decision Date
2025-01-28
Location
Indiana
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop and refine gene editing therapies, specifically utilizing CRISPR-Cas9 technology, to target the genetic roots of congenital neuromuscular disorders. Her work focuses on identifying underlying genetic mechanisms of hereditary muscular atrophy to create precise clinical interventions. The goal is to improve patient outcomes and reduce the long-term economic burden of diseases like Duchenne muscular dystrophy on the U.S. healthcare system.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses severe congenital disorders like Duchenne muscular dystrophy, which has significant implications for U.S. public health and economic stability.

2 Well-positioned to Advance the Endeavor Met

The petitioner's extensive publication record, high citation count, and funding from the NIH demonstrate her capability to lead this research.

3 Waiver Benefit Met

The urgency of developing treatments for hereditary conditions and the petitioner's unique expertise make it beneficial to waive the job offer requirement.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 17 peer-reviewed journal articles, 6 conference abstracts, and 539 citations. Evidence included service as a manuscript reviewer for 5 journals and research funding from the National Institutes of Health (NIH) and Parent Project Muscular Dystrophy (PPMD). These achievements satisfied all three prongs of the Dhanasar framework.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Grants
Conference Presentations
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Research Scientist

Biotechnology · Brazil

WeGreened EB-2 (NIW) approved
Ohio 49 days 2025-05-23
The petitioner proposes to develop novel models of neuronal cells and apply gene therapy for the treatment of neuromuscular disorders. Her work focuses on using AAV-based gene therapies and CRISPR-adapted gene editing to enhance muscle regeneration and restore function in patients with conditions like DMD and CMD.
View Case

Doctor

Healthcare · Israel

WeGreened EB-2 (NIW) approved
Ohio 56 days 2024-12-17
The petitioner proposes to advance the understanding of complex genetic disorders through the development of innovative genetic engineering models and tailored drug design methodologies. This work specifically focuses on investigating somatic mutations in the brains of individuals with Alzheimer’s disease to identify new pathways for diagnosis and therapeutic intervention. The endeavor aims to support the medical community in treating neurodegenerative processes and syndromic autism.
View Case

Postdoctoral Researcher

Biotechnology · South Korea

WeGreened EB-2 (NIW) approved
California 249 days 2025-05-28
The petitioner proposes to develop advanced biological tools for genetic and molecular cell interfacing, specifically focusing on high-precision CRISPR base editors and synthetic protein biomarkers. This work aims to refine viral vector delivery systems to enable targeted, non-invasive gene therapies for complex neurological diseases.
View Case

Others

Biotechnology · United Kingdom

WeGreened EB-2 (NIW) approved
486 days 2025-04-12
The petitioner proposes to advance diagnostic capabilities for genetic and neurological disorders through research in biomechanics and computational biology. The work focuses on designing cutting-edge algorithms for medical image analysis, specifically utilizing 3D scans to enhance early detection and treatment precision. These innovative tools are intended to provide timely medical interventions and improve healthcare outcomes for vulnerable populations.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-01-28.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 122 days
Criteria Met 3 / 3
Evidence Types 7

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist